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ADAM9 (A Disintegrin And Metalloproteinase 9) is a member of the ADAM protein family which contains
a disintegrin domain. This protein family plays key roles in many physiological processes, including
fertilization, migration, and cell survival. The ADAM proteins have also been implicated in various dis-
eases, including cancer. Speciﬁcally, ADAM9 has been suggested to be involved in metastasis. To address
this question, we generated ADAM9 knockdown clones of MDA-MB-231 breast tumor cells using
silencing RNAs that were tested for cell adhesion, proliferation, migration and invasion assays. In RNAi-
mediated ADAM9 silenced MDA-MB-231 cells, the expression of ADAM9 was lower from the third to the
sixth day after silencing and inhibited tumor cell invasion in matrigel by approximately 72% when
compared to control cells, without affecting cell adhesion, proliferation or migration. In conclusion, the
generation of MDA-MB-231 knockdown clones lacking ADAM9 expression inhibited tumor cell invasion
in vitro, suggesting that ADAM9 is an important molecule in the processes of invasion and metastasis.
 2013 Elsevier Masson SAS. Open access under the Elsevier OA license.1. Introduction
Attachment of cells to the extracellular matrix (ECM) depends
mainly on a family of glycoproteins known as integrins [1], which
are expressed on the cell surfaces of many cultured cell types at
specialized adhesion sites known as focal contacts [2]. A number of
structural and signaling proteins, such as integrins, cytoskeletal
proteins, and kinases are concentrated at these sites and are
known to initiate signal transduction pathways [3,4]. The aggre-
gation of integrin receptors, ligand occupancy and tyrosine kinase-
mediated phosphorylation are the key events that result in
different processes, including cell migration, differentiation, tissue
remodeling, cell proliferation, angiogenesis, tumor cell invasion
and metastasis [1,5].
Members of the ADAM (an acronym for A Disintegrin And
Metalloprotease) protein family are involved in several humanento de Gerontologia, Rodo-
arlos, SP, Brazil. Tel.: þ55 16
etti).
nder the Elsevier OA license.diseases such as inﬂammatory disorders, neurological diseases,
asthma and cancer metastasis [6,7]. ADAM9 is a transmembrane
protein with a number of characteristic domains, including a pro-
domain, a metalloproteinase domain, a disintegrin-like domain, a
cysteine-rich region, a transmembrane domain, and a short cyto-
plasmic tail [8]. The ADAM9 disintegrin domain binds to numerous
integrins, such as a6b1 integrins in ﬁbroblasts [9], aVb5 in myeloma
cells [10] and aVb3 in MDA-MB-231 breast tumor cells [11].
Mahimkar et al. [12] and Zigrino et al. [13] have demonstrated that
the recombinant disintegrin and cysteine-rich domains from hu-
man ADAM9 mediate cellular adhesion through b1 integrins.
Furthermore, the disintegrin-like and cysteine-rich domains of
ADAM9 mediate interactions between melanoma cells and ﬁbro-
blasts [14].
Over-expression of ADAM9 has been reported in several human
carcinomas, including kidney [15], prostate [16], breast [17], liver
[18,19], pancreatic [20], gastric [21], cervix [22] and oral [23].
Expression of ADAM9 is elevated in skin melanoma but is restricted
to the invading front [24]. Peduto et al. [25] found a correlation
between ADAM9 titer and cancerous changes in mouse models of
prostate cancer, especially in well-differentiated tumors. Increased
expression of ADAM9 led to increased structural abnormalities and
growth of early-stage tumors compared to controls.
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signaling systems. In prostate cancers, the ﬁbroblast growth factor
(FGF) signaling pathway is believed to be particularly important
[26], with down-regulation of the ﬁbroblast growth factor receptor
2 isoform IIIb (FGFR2IIIb) being a feature of prostrate tumor pro-
gression [27]. Transfection of FGFR2IIIb into malignant tumors is
enough to inhibit their growth [28]. Therefore, it is potentially
signiﬁcant that over-expression of ADAM9 increases shedding of
FGFR2IIIb from cells, which is expected to disrupt FGFR2IIIb
signaling and reduce its function [25]. Additionally, over-expression
of ADAM9 leads to increased release of epidermal growth factor
(EGF) [25], a factor known to induce prostate cancer growth in rat
pups [29].
Although ADAM9 is normally considered a transmembrane
protein, a soluble form ADAM9-S has been described [30], which is
derived from alternative splicing of the gene [31]. The ADAM9-S
protein promotes the invasive phenotype of carcinoma cell lines,
and ADAM9 is strongly expressed at the invading front of hepatic
metastases, although the authors did not distinguish ADAM9 and
ADAM9-S [31]. Taken together, these studies suggest that ADAM9
has a signiﬁcant role in tumorigenesis and metastasis.
To better understand the role of ADAM9 in breast cancer pro-
gression, we generated knockdown clones lacking ADAM9 using
RNAi in theMDA-MB-231 human breast tumor cell line. As far as we
know, this is the ﬁrst demonstration that decreased ADAM9
expression impaired the invasiveness of this cell line. In addition,
the present work demonstrated, for the ﬁrst time, ADAM9 silencing
in a breast tumor cell line and provided evidence that ADAM9 may
play an important role in the metastatic progression of human
breast cancer.
2. Material and methods
2.1. Cell culture
MDA-MB-231 breast tumor cells were cultivated in DMEM
medium (Invitrogen) containing 10% bovine fetal serum (FBS), L-
glutamine (2 mM), penicillin (100 U/ml), streptomycin (100 mg/ml)
and amphotericin B (250 mg/ml) (Invitrogen) in 5% CO2 at 37 C. The
anti-ADAM9 antibody was from Abcam (anti-RP2ADAM9) and the
anti-b-actin antibody was from Santa Cruz Biotech (sc-1616).
2.2. Design of siRNA primers
Primer set #104056, which targets exon 13 (disintegrin domain)
(Silencer Pre-designed siRNA, Ambion), was selected to ensure
that other ADAMs would not be silenced simultaneously. The
primer sequences were: sense (50-rCrCrArGrArGrUrArCrUrGrCrAr-
ArUrGrGrUrUrCrUrUrCTC-30) and antisense (50-rGrArGrArArGrAr-
ArCrCrArUrUrGrCrArGrUrArCrUrCrUrGrGrArA-30). The negative
control (scrambled) used in the assays was Silencer Select Nega-
tive Control No. 1 siRNA (Ambion). This sequence does not target
any gene product and have no signiﬁcant sequence similarity to
human gene sequences, being essential for determining the effects
of siRNA delivery.
2.3. ADAM9 RNA silencing
On the day before transfection, 2  105 MDA-MB-231 cells were
plated in 5 ml of DMEM medium supplemented with 10% FBS
without antibiotics. Ten microliters of lipofectamine were mixed
with 490 ml OPTI-MEM serum-free medium (Invitrogen) and
incubated at room temperature for 5 min. A total of 10 nM of RNA
silencing primer was diluted in OPTI-MEM, added to the lipofect-
amine/OPTI-MEM mixture and incubated for 20 min at roomtemperature. This mixturewas then added to the cells. Themedium
was changed 24 h after transfection. Controls comprised of non-
treated cells, cells treated with transfection reagent only (lip-
ofectamine), and cells treated with a scrambled primer. Cells were
washed in phosphate buffered saline, harvested with Trizol reagent
(Invitrogen) according to the manufacturer’s protocol, and frozen
immediately. For western blotting assays, cells were lysed with
Triton X-100 in Hepes buffer [150 mM NaCl, 50 mM Hepes, 1.5 mM
MgCl2, 1% Triton X-100, 0.1% SDS, protease inhibitor cocktail
(Sigma), 100 mMNaF and 100 mM Na3VO4]. Protein concentrations
in the lysed samples were determined by the BCA method (Pierce),
and 30 mg of each sample was resolved by SDS-PAGE [32]. Protein
bands were transferred to nitrocellulose membranes and probed
with anti-RP2ADAM9 and anti-b-actin antibodies. Western blots
were scanned on an Image Scanner (GE e General Electric). All the
assays using ADAM9 knockdown MDA-MB-231 cells were per-
formed after the third day of siRNA transfections.
2.4. Extraction of RNA and synthesis of cDNA
Total RNA was extracted from cells using Trizol reagent (Invi-
trogen) following themanufacturer’s instructions. All samples were
treated with DNase I (Deoxyribonuclease I, Ampliﬁcation Grade,
Invitrogen). After quantiﬁcation, a total of 1 mg of RNA was mixed
with 0.5 ml of oligo dT (0.5 mg/ml) (Promega) and nuclease-free
water to a volume of 7 ml and incubated at 70 C for 5 min, fol-
lowed by 5 min on ice. Next, 0.5 ml of 200 units/ml of Moloney
Monkey Leukemia virus (MMLV) reverse transcriptase (Promega),
2.5 ml of 5MMLV buffer (Promega), and 2.5 ml of 10 mM dNTP mix
was added to the reaction. The whole mixture was incubated at
37 C for 1 h, and was used posteriorly for qPCR.
2.5. Design of qPCR primers
ADAM9 primers targeting the disintegrin domainwere designed
using Primer3Plus software (http://www.bioinformatics.nl/cgi-bin/
primer3plus/primer3plus.cgi). Primers spanned exon boundaries
so that only mRNA sequences would be ampliﬁed. The primers
were ADAM9DF1 (50CTT GCT GCG AAG GAA GTA CC); and
ADAM9DR1 (50AAC ATC TGG CTG ACA GAA CTG A). Primers tar-
geting HPRT1F1 (50TGA CAC TGG CAA AAC AAT GCA), HPRT1R1
(50GGT CCT TTT CAC CAG CAA GCT), GAPDHF1 (50GAT GCT GGT GCT
GAG TAT GT) and GAPDHR1 (50GTGGTG CAG GAT GCATTG CT) were
used as endogen controls.
2.6. Gene expression
ADAM9 mRNA expression was measured in a Corbett Rotor-
gene RG 3000 (Corbett Research) using the following thermocy-
cling conditions: 95 C for 10 min, followed by 40 cycles of
ampliﬁcation at 95 C for 15 s, 55 C for 5 s and 72 C for 20 s. The
master mix in eachwell consisted of 12.5 ml ABsoluteTMQPCR SYBR
Greenmix (6mMMgCl2, reaction buffer, DNA polymerase and SYBR
green dye) (Advanced Biotechnologies), 1.25 ml each of 5 mM for-
ward and reverse primer and 10.5 ml of nuclease-free water in a
total volume of 25 ml.
2.7. Proliferation assays
Tomeasure the effect of RNAi-mediated ADAM9 silencing on cell
proliferation the transition of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) to formazan was used [33].
Cells without any treatment, cells treated only with lipofectamine,
and cells transfected with siRNAs were seeded in 96-well plates
and left at 37 C for 24 and 48 h. The cells were then washed with
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37 C for 4 h. Following the addition of 100 ml of isopropanol, the
absorbance was read at 595 nm in an ELISA plate reader. The mean
proliferation of cells without any treatment was expressed as 100%.
2.8. Adhesion assays
The effect of RNAi-mediated ADAM9 silencing on the adhesion
of MDA-MB-231 cells was analyzed in 96-well plates (Corning).
A solution of type I collagen (10 mg) was immobilized on the plates
in 0.1% acetic acid. Fibronectin and laminin (10 mg) were dissolved
in adhesion buffer (20 mM HEPES, 150 mM NaCl, 5 mM KCl, 1 mM
MgSO4 and 1 mM MnCl2 pH 7.35), overnight at 4 C. On the next
day, the wells were blocked with a solution of 1% BSA diluted in
adhesion buffer for 1 h. Cells were counted and their concentration
was adjusted in proportion to 5106/ml. The blocking solutionwas
removed from thewells and theywerewashed twicewith adhesion
buffer (100 ml). After this period the cells were incubated for 45min
on the coatings and subsequently wells were washed in order to
remove non-adherent cells. A solution of 70% ethanol (100 ml) was
added to the wells and the plate was incubated for 10 min at room
temperature. Subsequently, the ethanol was removed and 60 ml of
crystal violet (0.5%) was added and incubated for 20 min at room
temperature. After this time, the solution containing the crystal
was removed and the wells were washed with PBS to remove
excess. Finally 100 ml of 1% SDSwas added and incubated for 30min
at room temperature. The reading of absorbance was performed at
a wavelength of 595 nm, and three treatments were compared,
including cells without any treatment, cells treated only with lip-
ofectamine, and cells transfected with siRNAs. The adhesion of
control cells to each substrate was determined as 100%.
2.9. Wound healing assay
Wound-healing migration assay is based on the repopulation of
wounded cultures. The cells were seeded into 24-well culture
plates at 1 105 cells/well and the cell monolayer were cultured in
medium containing 10% FBS until reach 100% of conﬂuence. The
monolayers were carefully wounded using a yellow pipette tip, and
any cellular debris present was removed by washing twice with
DMEMmedium. The wounded monolayers were then incubated in
DMEM medium containing 10% FBS. Photographs of the exact
wound areas taken initially (0 h) were again taken after 16 and 24 h.
The images were compared between three treatments, including
cells without any treatment, cells treated only with lipofectamine,
and cells transfected with siRNAs, and with or without incubation
with the ADAM9D protein [11]. Photographs were analyzed using
ImageJ software and the formula of % of wound closure [34].
2.10. Cell migration
Cell migration was assessed in 24 well Boyden chambers (BD
Biosciences). MDA-MB-231 (5  104) cells were seeded on the up-
per chamber in FBS-free DMEM medium. DMEM containing FBS
(10%) was added to the bottom chamber and acted as a chemo-
attractant. Tumor cells were allowed to migrate for 22 h at 37 C
and 5% CO2 in a humidiﬁed environment. Then, the cells that
remained in the upper chamber were removed using a cotton swab.
The cells that migrated to the other side of the upper chamber
membranewere ﬁxed withmethanol and stainedwith 1% toluidine
blue in 1% borax. Cells were counted using the ImageJ software
(public domain software) in 5 ﬁelds (100 magniﬁcation) per well
that essentially covered 80% of the well surface. The average
number of cells from each of the triplicates represents the average
number of cells that migrated in the different groups. Eachexperiment had triplicate wells for every treatment group and we
repeated each experiment three times. The mean of all results from
controls was considered as 100%. After that, the images were
compared among three treatments, including cells without any
treatment, cells treated only with lipofectamine, and cells trans-
fected with siRNAs.
2.11. Matrigel invasion assay
Cellular invasion assays were carried out using BioCoat Matrigel
Invasion Chambers (BD Biosciences) with 8-mm pores in 6-well
plates. A total of 2.5  104 cells were added to each chamber.
Complete medium was used as a chemoattractant in the lower
chamber. After incubation for 22 h at 37 C and 5% CO2, cell invasion
was measured in the same way as performed for migration assay
(item 2.10). The invasion of cells without any treatment was
determined as 100%.
2.12. Gelatin zymography
The effect of ADAM9 silencing on the proteolytic activity of
MDA-MB-231 cells was determined by zymography [35]. MDA-MB-
231 cells (2  106) in FBS-free DMEMmediumwere seeded in 6-cm
dishes. After incubation for 24 h at 37 C and 5% CO2, cells were
lysed with a buffer containing TriseHCl (0.2 M) (pH 7.4) and Triton
X-100 (0.2%). The cell lysates were centrifuged (10min at 13,000 g
and 4 C), and the supernatants were separated. The total protein
concentration in each sample was measured using the BCA color-
imetric detection kit (BCA Protein Assay, Pierce). Protein samples
(20 mg) were subjected to electrophoresis under non-reducing
conditions in 10% SDS polyacrylamide gels containing 1 mg/ml
gelatin. After electrophoresis, gels were washed twice in 2.5% of
Triton X-100 to remove SDS and incubated in substrate buffer
[50 mM TriseHCl (pH 8.0); 5 mM of CaCl2 and 0.02% NaN3] at 37 C
for 20 h. To conﬁrm the metalloproteinase activity, EDTA in a ﬁnal
concentration of 15 mM was added to the samples and substrate
buffer. Proteins were stained with Coomassie brilliant blue for 1.5 h
and destained with an acetic acid, methanol and water mixture (in
a 1:4:5 v:v:v ratio). Gels were photographed with a Canon G6 Po-
wer Shot 7.1 machine. Gelatinase activity was visualized as clear
bands in the stained gels, and the average band intensities was
measured using the Gene Tools v3.06 software (Syngene). MMP-2
and MMP-9 activity were quantiﬁed as arbitrary units and
compared between three treatments, including cells without any
treatment, cells treated only with lipofectamine, and cells trans-
fected with siRNAs.
2.13. Statistical analysis
For all assays, each experiment was repeated three times in
triplicate (independent experiments), and standard errors of the
mean were calculated. The results were compared statistically us-
ing a one-way analysis of variance (ANOVA) and Tukey’s test was
applied for multiple comparisons. All statistical tests used p  0.05
as a cut-off for signiﬁcance. Cases where p < 0.05 were marked as
follows: *p < 0.05, **p < 0.01 and ***p < 0.001.
3. Results
3.1. ADAM9 silencing is detected at the mRNA and protein levels
ADAM9 gene expression was dramatically decreased in MDA-
MB-231 cells treated with siRNAs at both the mRNA and protein
(Fig. 1A and B, respectively) levels when compared to the controls
(MDA-MB-231 cells without treatment and lipofectamine or
Fig. 1. Silencing of ADAM9. (A) Expression of ADAM9 mRNA in RNAi-mediated ADAM9 silenced MDA-MB-231 cells was analyzed by qPCR. The values are in arbitrary units (AU) and
the p value was determined using ANOVAwith a Tukey’s test comparing control, cells treated with lipofectamine, negative control (scrambled) and cells treated with ADAM9 siRNAs
(***p < 0.001). (B) Western blotting analysis of MDA-MB-231 cell lysates, with three treatments: cells alone (C), lipofectamine alone (L), and ADAM9 siRNAs using anti-ADAM9RP2
primary antibody and goat anti-rabbit IgG as a secondary antibody. b-actin was used as endogen control. (C) The silencing of ADAM9 using siRNAs is transient because it is effective
only from the third to the sixth day. The values are in arbitrary units (AU).
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of 91.35  6.32% of ADAM9 expression in RNAi-mediated knock-
down MDA-MB-231 cells when compared to control cells (Fig. 1A).
At the protein level, western blotting analysis using anti-ADAM9
antibody presented similar results (Fig. 1B).
Gene silencing using synthetic duplexes siRNA is transient. As a
result, 10 plates (6-cm) containing 2  105 MDA-MB-231 cells were
silenced. One plate was removed randomly each day to determine
the efﬁciency of ADAM9 silencing over time. RNA knockdown was
measured from the third to the eleventh day after transfection and
the kinetics of ADAM9 silencing in MDA-MB-231 cells are shown in
Fig. 1C. The highest efﬁciency of ADAM9 silencing was observed
from the third to the sixth days, although on the seventh and eighth
days, the gene expression still remained low. From the ninth and
tenth days onwards, the expression of ADAM9 expression increased
exponentially and reached similar levels to those obtained by
control cells (Fig. 1C).
3.2. ADAM9 silencing does not affect MDA-MB-231 cell
proliferation or adhesion
ADAM9 silencing had no effect on the proliferation of MDA-MB-
231 cells on the third (Fig. 2A) or sixth (Fig. 2B) days after silencingFig. 2. Proliferation assay. Silencing of ADAM9 had no effect on the proliferation of the MDA-
cells were incubated with MTT for 24 h or 48 h and compared with control cells or with lipof
proliferation of control cells was determined as 100%.in 24 or 48 h of incubation. No signiﬁcant differences were
observed among the groups. ADAM9 silencing also had no effect on
the adhesion of MDA-MB-231 cells to different ECM proteins, such
as collagen type I, ﬁbronectin or laminin (Fig. 3).
3.3. ADAM9 silencing strongly inhibits MDA-MB-231 cell invasion
without affecting cell migration
RNAi-mediated ADAM9 silencing was not able to signiﬁcantly
inhibit the migration of MDA-MB-231 human breast tumor cells
when compared with non-transfected cells or with lipofectamine-
transfected cells after 16 (Fig. 4A) or 24 h that the wounds were
made (Fig. 4B). ADAM9 knockdown cells were incubated with
different concentrations of ADAM9D, the disintegrin domain of
ADAM9 [11]. ADAM9D in concentrations of 500, 1000 and 2000 nM
had no effects in inhibiting ADAM9 knockdown MDA-MB-231 cell
migration after 16 (Fig. 4A) or 24 h (Fig. 4B) of incubation. Photo-
graphs were taken after 0, 16 or 24 h after wound (Fig. 4C).
To ensure these results we also performed migration assays
using Boyden chambers. RNAi-mediated ADAM9 silencing had had
no effect on MDA-MB-231 cell migration when compared with
control cells or lipofectamine-treated cells after 22 h of incubation
(Fig. 5A and B).MB-231 cells after three (A) or six days (B) of transfection. After the different times, the
ectamine-treated cells. The absorbance of the samples was measured at 595 nm and the
Fig. 3. Adhesion assay. RNAi-mediated ADAM9 silencing had no effect on the adhesion
of the MDA-MB-231 under different extracellular matrix proteins, such as collagen I
(Col. I), ﬁbronectin (FN) and laminin (LA). The extracellular matrix proteins were
coated on the wells of the plate, and on the following day, after the blocking of wells,
the cells were allowed to adhere for 45 min. The percentage adhesion was determined
as described in the materials and methods. The results were compared using a one-
way analysis of variance (ANOVA), followed by a Tukey’s post-hoc analysis.
Fig. 5. Effect of RNAi-mediated ADAM9 silencing on migration of MDA-MB-231 cells.
(A) A transwell migration assay was used to determine the effect of ADAM9 silencing
migration of MDA-MB-231 cells. Control cells, lipofectamine-treated cells or siRNA-
ADAM9 cells were allowed to migrate toward medium containing 10% FBS for 22 h.
Graphs are representative of three independent experiments. The results were
compared using a one-way analysis of variance (ANOVA), followed by a Tukey’s post-
hoc analysis (***p < 0.001). (B) Morphology of cells in the three different treatments:
control cells (Cþ), lipofectamine-treated cells (L), and siRNA-ADAM9 treated cells
(siRNA) migrating toward a 10% FBS containing medium. The negative control (C) was
control cells migrating toward a FBS-free medium. Bar represents 10 mm.
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MB-231 cells strongly inhibited the invasion in an in vitro matri-
gel assay by 71.518.02% when compared to control untransfected
cells (Fig. 6A). Lipofectamine and negative control-transfected cells
(scrambled) remained invasive and no statistically signiﬁcant dif-
ferences were observed when compared to untransfected cells
(Fig. 6A). Photographs were taken after 22 h of incubation (Fig. 6B).Fig. 4. Migration of MDA-MB-231 cells after wounding. Effects of ADAM9 silencing and ADAM
of wound closure in 16 (A) or 24 h (B) after wounding. Representative photos of wounds w
pictures representing control (C), lipofectamine (L) and siRNA-ADAM9 (siRNA) cells withou3.4. MMP-2 and MMP-9 concentration and activity
In order to investigate the mechanisms involved in the inhibi-
tion of the invasion ability of RNAi-mediated ADAM9 silencing of9D recombinant protein on MDA-MB-231 cells migrationwere plotted as a percentage
ere taken at time zero, 16 h, and 24 h after wounding, (C). In these photos we show
t previous treatment with ADAM9D recombinant protein.
Fig. 6. Effect of RNAi-mediated ADAM9 silencing on the invasion of MDA-MB-231
cells. ADAM9 silencing signiﬁcantly inhibits the invasion of MDA-MB-231 human
breast tumor cells through matrigel compared to the invasion of control cells (A). The
cells were plated in wells containing matrigel and FBS was used as a chemoattractant
in the lower chamber. The invasive cells were ﬁxed and counted (an average of eight
ﬁelds from each treatment). The assay was performed in triplicate. The results were
compared using a one-way analysis of variance (ANOVA), followed by a Tukey’s post-
hoc analysis (***p < 0.001). (B) Cell morphology in the four different treatments:
untreated control (C), lipofectamine-treated cells (L), scrambled siRNA-treated control
(S), and siRNA-ADAM9 treated cells (siRNA). Bar represents 10 mm.
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the activity of MMP-2 and MMP-9. There was no variation in the
total concentration of MMP-2 or MMP-9 among the three treat-
ment types analyzed in this study, as demonstrated by 1% gelatin-
SDS-PAGE (Fig. 7A). The incubation with EDTA resulted in the in-
hibition of MMP-2 and 9 activities conﬁrming the nature of met-
alloprotease activity (Fig. 7B). The average activity of MMP-2 and
MMP-9 was measured as indicated in Section 2.12 and plotted on aFig. 7. Analysis of concentration and activity of MMP-2 and MMP-9 in the MDA-MB-231 br
Lane 1: molecular mass marker; lanes 2e4: control cells; lanes 5e7: cells treated with lipofec
was loaded in each lane). (C) MMP-2 and (D) MMP-9 concentrations were determined by the
analyzed by densitometry, and activity was expressed as arbitrary units.graph (Fig. 7C and D, respectively). This result suggests that RNAi-
mediated ADAM9 silencing does not affect the activity of MMP-2
or MMP-9.
4. Discussion
The progression of malignant tumors results from the invasion
of the primary tumor to a secondary site, causing metastasis in a
multi-step process that requires cellecell and cellematrix in-
teractions within the host tissue. These steps can be summarized as
follows: cell detachment from the primary tumor, migration into
the ECM, intravasation into a blood or lymphatic vessel, survival
within the vasculature, adherence of these tumor cells in the
endothelium, extravasation, and formation of secondary tumors
[36,37]. These interactions lead to the production, release and
activation of a variety of cytokines and growth factors and subse-
quent generation of signals to directly or indirectly promote tumor
growth and survival [24]. Different proteases have been implicated
in these processes, such as MMPs, ADAMs and ADAMTSs [7,24,38].
Due to the strong involvement of ADAM9 in the metastatic
process, in this study we have generated knockdown clones of
MDA-MB-231 human breast tumor cells that lack ADAM9 expres-
sion and then tested these clones to their ability to adhere, migrate,
proliferate and invade through ECM using in vitro assays. The RNAi-
mediated silencing in MDA-MB-231 cells was very successful, with
more than 90% of ADAM9 knocked down, as estimated by quanti-
tative PCR and western blotting analysis. The expression of ADAM9
was easily silenced using a relatively small (10 nM) concentration of
ADAM9 siRNAs. A similar result was obtained by other investigators
in highly invasive SCC68 cells, a squamous cell carcinoma cell line,
but with tenfold higher concentration of siRNAs (100 nM) [39].
Using a matrigel invasion assay, we showed that the ADAM9
silencing signiﬁcantly inhibited the invasion capacity of MDA-MB-
231 human breast cancer cells, which suggests that this protein
plays an important role in cell invasion. However, the silencing of
ADAM9 had no effect on MDA-MB-231 cell adhesion, migration,
proliferation, or MMP-2 and 9 activities. Our results showed that
ADAM9 silencing had no impact on MMP-2 and MMP-9 expression
or gelatinase activity indicating that reduced invasion in cellseast tumor cells. (A) Zymography in 1% gelatin-SDS-PAGE or (B) EDTA-treated samples.
tamine; and lanes 8e10: cells treated with ADAM9 siRNAs (n ¼ 3; 20 mg of total protein
sum of integrated optical density (IOD) obtained for the intermediate bands. Gels were
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of MMP-2/9. We propose that ADAM9 proteolytic activity may
directly contribute to matrigel invasion byMDA-MB-231 cells since
ADAM9 has been reported to cleave laminin [31], a major constit-
uent of matrigel.
Shintani et al. [40] showed that the overexpression of ADAM9
enhances adhesion and cell invasion in lung cancers, via modula-
tion of other adhesion molecules and changes in sensitivity to
growth factors. According to this study, ADAM9 may either directly
degrade the ECM or induce the activation of other proteases in the
ECM, such as matrix MMPs, thereby allowing tumor cell penetra-
tion into the brain matrix.
Our results are in agreement with Mazzocca et al. [31] who
showed that ADAM9-S, an alternatively spliced variant secreted by
activated hepatic stellate cells, induces colon carcinoma cell inva-
sion in vitro and that this process requires both protease activity
and binding to the a6b4 and a2b1 integrins.
Contradictorily to our results, Fry and Toker [41] demonstrated
that the silencing of both soluble (ADAM9-S) and transmembrane
(ADAM9-L) isoforms, increased the migration of BT549 breast
cancer cells. In this work, they also showed that the overexpression
of ADAM9-S is responsible for increasing cell migration in BT549
cells through its metallopeptidase domain. Moreover, they also
showed that ADAM9-L is responsible for inhibiting cell migration
through its disintegrin domain. Thus, both isoforms have different
and opposite responses during cancer progression. Whether MDA-
MB-231 cells have ADAM9-S and L isoforms and the effects of
isoform silencing in this cell line will be further investigated.
Some ADAMs may induce proliferation by catalyzing the
cleavage of growth factors, such as HB-EGF, and its membrane
anchored form (proHB-EGF) can act as a negative regulator of
proliferation [42,43]. Izumi et al. [44] showed that after induction
with TPA (an activator of protein kinase C), ADAM9 interacted with
PKCd and cleaved proHB-EGF; however, we have demonstrated
here that ADAM9 is not involved in the proliferation of MDA-MB-
231 cells. In another work, RNAi-mediated ADAM9 silencing was
responsible by a reduction in adenoid cystic carcinoma metastasis
both in vitro and in vivo [19]. In this work, the authors also
demonstrated that ADAM9 is essential for cancer cell proliferation
and invasion and that its expression could be used as a prognostic
of metastatic risk, since it was elevated in a high metastatic po-
tential cell line (SACC-LM) when compared to a low metastatic
potential cell line (SACC-83) [19].
Klessner et al. [39] demonstrated that ADAM9 participates in the
shedding of desmoglein 2 (Dsg2), resulting in stronger cellecell
adhesion, which could, in turn, reduce the rate of migration and
cell invasion. The ADAMs can also interact with b1 integrins, and
this association facilitates the recognition and location of their
substrates for proteolytic shedding [45,46], as reported by
Mahimkar et al. [47].
In a recent work, Hamada et al. [48] reported that miR-126 was
found to target ADAM9 and that siRNA-based knockdown of
ADAM9 in pancreatic cancer cells resulted in reduced cellular
migration, invasion, and induction of epithelial marker E-cadherin.
Taken together, the literature results and the data found in the
present study suggest that ADAM9 participates in the invasion of
tumor cells by either directly degrading the ECM, by inducing
activation of other proteases, such as MMPs, by co-localizing with
other molecules, such as b1 integrin, present on the surface of MDA-
MB-231 cells (data not shown) or by interacting with other regu-
lators such as miRNAs. A more conclusive demonstration that
ADAM9 is a suitable target for metastatic breast cancer will require
the use of a stable expression vector in vivo and/or inhibitors of
this protein alone or in combination with conventional clinical
therapies.5. Conclusions
The results presented in this study reinforce the importance of
the ADAM9 role in the invasion of breast tumor cells. Considering
the signiﬁcance of cell invasion in metastatic progression, ADAM9
can be pointed as an interesting target for the design of drugs
involved in the treatment or prevention of breast cancers. We
conclude that ADAM9 has an essential role in cell invasion and may
be involved inmetastatic spread. Therefore, it may be an interesting
target for anti-metastatic therapy.
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